9 results about "Obstructive azoospermia" patented technology

This invention provides a biomarker for spermatogenesis disorders and its application, wherein the biomarker is the MNDA molecule. This application characterizes the functional abnormalities or spermatogenesis disorders of Sertoli cells by detecting the expression level of MNDA molecules on cells in testicular tissue sections, and can therefore be used for the clinical diagnosis of non-obstructive azoospermia.

The invention discloses a method for distinguishing obstructive azoospermia and non-obstructive azoospermia based on ultrasonic images and machine learning, and relates to the technical field of image analysis and machine learning, all patients are subjected to bilateral scrotum ultrasonic examination before operation; patients are divided into a training set, a validation set, and a test set according to the use of the dataset. In the training set, image omics features are extracted from the left testis ultrasonic image and the right testis ultrasonic image, and key features related to obstructive azoospermia are screened out; on the basis of the selected radiomics features, five machine learning models are constructed, including a k-nearest neighbor model, a logistic regression model, a multi-layer perceptron model, a random forest model and a support vector machine model; analyzing and evaluating the diagnostic performance and clinical application value of the model in the three groups of data through an ROC curve and a clinical decision curve; and explaining the final machine learning model by using SHAP analysis. The method has important value in distinguishing obstructive azoospermia and non-obstructive azoospermia, wherein the logistic regression model shows better diagnostic performance compared with other four models.

The invention provides a product related to non-obstructive azoospermia microscopic sperm extraction, application and a method. The invention discloses application of a reagent for detecting clinical information in preparation of a non-obstructive azoospermia microscopic sperm extraction product. The clinical information comprises age, testis size, testosterone, estradiol E2, androgen T, follicle stimulating hormone FSH, statin B and seminal plasma cell-free DNA motif diversity score. The prediction method comprises the following steps: acquiring clinical information of a to-be-tested object; inputting the clinical information into a prediction model based on machine learning to obtain a probability P of successful microscopic sperm extraction; and according to comparison between the probability P and a reference value, diagnosing or predicting whether the to-be-detected object is suitable for microscopic sperm collection. The prediction method provided by the invention can be used for improving the accuracy of predicting the success rate of microscopic sperm extraction of non-obstructive azoospermia, and has a relatively good clinical application value.

The invention discloses a method for constructing an azoospermia mouse model by knocking out a UBC9 gene of a germ cell and application of the azoospermia mouse model, the construction method is to knock out the UBC9 gene on a mouse germ cell genome, and the knockout is carried out by using a Cre-LoxP system. The azoospermia mouse model constructed by the invention can be used for research on non-obstructive azoospermia and corresponding drug research and development. The model mouse shows that the testis weight and volume are reduced, a large number of germ cells are deleted, meiosis is stopped, and mature sperms are completely deficient.

The present invention provides the use of the RBBP7 gene / protein as a drug target in the preparation of products for the diagnosis and treatment of male infertility. Experiments have shown that mutant RBBP7 genes / proteins lead to male infertility, spermatogenesis disorders, spermatogenesis arrest, and azoospermia. The mutant RBBP7 gene / protein of the present invention and one of its pathogenic mutation sites can be used as target genes for the diagnosis of male infertility. Furthermore, the expression level of RBBP7 in the RBBP7 gene / protein is significantly reduced in patients with non-obstructive azoospermia. By increasing the activity and / or expression of the RBBP7 protein, male infertility can be prevented and / or treated.

The invention relates to the technical field of assisted reproduction polygene detection, and discloses a non-obstructive azoospermia detection panel, a non-obstructive azoospermia detection kit and application of the non-obstructive azoospermia detection panel. The detection panel comprises mutant genes related to non-obstructive azoospermia, supportive cell syndrome and testis spermatogenesis arrest for detection, genes with copy number variation and genes with rearrangement events and deletion. By adopting the detection panel or the detection kit provided by the invention, accurate sequencing can be realized. The abnormal condition of the gene contained in the application is detected as a reference for clinical diagnosis of non-obstructive azoospermia (NOA), so that a doctor is helped to optimize NOA treatment measures and testis sperm extraction operation schemes and synchronously design an auxiliary treatment ovum extraction period; the method has important guiding significance for clinical diagnosis and treatment of NOA patients and male patients to be subjected to assisted reproductive technology treatment, evaluation of sperm obtaining success rate of the NOA patients before testis sperm extraction operation, precise treatment and potential personalized intervention measures.

The invention provides a kit or a chip (4 bile acids) for evaluating a spermatogenic function of a testis. The kit or the chip comprises detection reagents capable of detecting the concentrations of the following four bile acids: NorCA, GUDCA, T-alpha-MCA and GDCA. The invention further provides a kit or chip (10 bile acid) for evaluating the spermatogenic function of the testis. The kit or chip comprises detection reagents capable of detecting the concentration of the following ten bile acids: THCA, NorCA, TDCA, GHCA, GLCA, GUDCA, GCDCA, GCA, T-alpha-MCA and GDCA. By detecting the concentration of a series of bile acids in the plasma of a patient, the evaluation of the spermatogenic function and other testis spermatogenic states of male infertility is reflected. The method is suitable for evaluating various testicular spermatogenesis disorder states such as non-obstructive azoospermia, oligospermia, asthenospermia and spermatogonia, has the advantages of no need of sperm collection, high noninvasiveness, high sensitivity and wide applicable population, and is suitable for evaluating the male fertility rate and assisting in formulating an individualized assisted reproduction diagnosis and treatment scheme.

The present application relates to the application of RNF20 gene in the preparation of therapeutic drugs for azoospermia caused by RNF20 gene mutation, and the therapeutic drugs. The present application rescues the non-obstructive azoospermia of the young mouse with RNF20 gene deletion by introducing the RNF20 gene expression vector into the testicular tissue of the mouse through microinjection and electrotransformation. Further, the non-obstructive azoospermia of the adult mouse with RNF20 gene deletion is rescued by adding an autophagy inhibitor in the microinjection.

The invention provides a dyszoospermia biomarker and an application thereof. The biomarker is an MNDA molecule. According to the application, the state of dysfunction or dyszoospermia of Sertoli cells is represented by detecting the expression level of MNDA molecules on cells in a testicular tissue slice, so that the application can be used for clinical diagnosis and the like of non-obstructive azoospermia.